Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

ASTELLAS Aktie

 >ASTELLAS Aktienkurs 
8.25 EUR    -2.2%    (Tradegate)
Ask: 8.422 EUR / 400 Stück
Bid: 8.252 EUR / 400 Stück
Tagesumsatz: 601 Stück
Realtime Kurs von 8 bis 22 Uhr!
ASTELLAS Aktie über LYNX handeln
>ASTELLAS Performance
1 Woche: +1,1%
1 Monat: -0,6%
3 Monate: -1,0%
6 Monate: -11,4%
1 Jahr: -17,2%
laufendes Jahr: -11,5%
>ASTELLAS Aktie
Name:  ASTELLAS PHARMA INC.
Land:  Japan
Sektor:  Gesundheit
ISIN/ Wkn:  JP3942400007 / 856273
Symbol/ Ticker:  YPH (Frankfurt)
Kürzel:  FRA:YPH, ETR:YPH, YPH:GR
Index:  Nikkei225
Webseite:  https://www.astellas.com/
Marktkapitalisierung:  14960 Mio. EUR
Umsatz:  1648327.94 Mio. EUR
EBITDA:  372539.37 Mio. EUR
Gewinn je Aktie:  0.147 EUR
Schulden:  717523.19 Mio. EUR
Liquide Mittel:  162563.11 Mio. EUR
Umsatz-/ Gewinnwachstum:  10.8% / -
KGV/ KGV lG:  48.25 / -
KUV/ KBV/ PEG:  1.28 / 1.61 / -
Gewinnm./ Eigenkapitalr.:  2.65% / 3.26%
Dividende je Aktie:  0.455 EUR
Dividendenrendite/ -schätzung:  5.6% / 5.86%
Div. Historie:  28.03.25 - 0.22681€
27.09.24 - 0.22866€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  ASTELLAS
Letzte Datenerhebung:  19.07.25
>ASTELLAS Eigentümer
Aktien: 1790 Mio. St.
f.h. Aktien: 1790 Mio. St.
Insider Eigner: 0.22%
Instit. Eigner: 51.96%
Leerverk. Aktien: -
>ASTELLAS Peer Group

 
19.07.25 - 11:36
Astellas Employee Intends Not to Appeal Conviction in China (Nippon)
 
Beijing, July 19 (Jiji Press)--A Japanese employee of Astellas Pharma Inc. in his 60s, who was sentenced to three years and six months in prison for espionage in China on Wednesday, has no intention to appeal the ruling for now, informed sources said Saturday. As China uses a two-tier court system, those who are dissatisfied with the first ruling can appeal to a higher court. In the Aste......
19.07.25 - 02:30
China′s jailing of Astellas employee could have gone differently: ex-envoy (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
17.07.25 - 12:01
Japan Urges China to Release Expats after Spy Conviction (Nippon)
 
Tokyo, July 17 (Jiji Press)--Japan expressed disappointment Thursday after a Chinese court convicted a Japanese employee of Astellas Pharma Inc. of espionage, and called for the swift release of the employee, as well as other Japanese expatriates being held in China on similar charges. The guilty ruling, issued Wednesday, was "extremely regrettable," Japanese Deputy Chief Cabinet Secretary ......
17.07.25 - 06:03
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "P (PR Newswire)
 
- Supporting Korean Startups' Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program - TOKYO, July 17, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas")......
16.07.25 - 19:36
Astellas Pharma sentencing highlights China risks for corporate Japan (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
16.07.25 - 09:36
Japanese Man Gets 42 Months for Spying in China (Nippon)
 
Beijing, July 16 (Jiji Press)--A Chinese district court Wednesday sentenced a Japanese man in his 60s to three years and six months in prison for espionage. The employee of Japanese drugmaker Astellas Pharma Inc. was detained by Chinese authorities in March 2023 shortly before leaving for Japan after completing his assignment term in China. He was indicted in August 2024, and the first h......
16.07.25 - 09:18
China jails Japanese businessman for espionage, embassy says (Al Jazeera)
 
Astellas Pharma employee sentenced to three and a half years in prison, Japan's embassy in Beijing says....
16.07.25 - 06:42
China jails Japan′s Astellas Pharma employee for 3.5 years for spying (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
11.07.25 - 02:36
China Court to Issue Ruling on Japanese Businessman on Wed. (Nippon)
 
Beijing, July 11 (Jiji Press)--A district court in Beijing will hand down a ruling Wednesday on a Japanese employee of Astellas Pharma Inc., who has been charged with espionage in China, sources familiar with Japan-China relations have said. Earlier this week, the court informed the Japanese Embassy in Beijing of the date of the sentencing hearing, and arrangements are being made for an emb......
10.07.25 - 13:27
Pfizer, Astellas say Xtandi regimen hit secondary goal in late-stage trial for prostate cancer (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.06.25 - 16:48
Nikon Instruments and Astellas announce a strategic collaboration to offer SakuLab-Cambridge MA resident companies access to advanced imaging capabilities provided by Nikon BioImaging Lab USA (PR Newswire)
 
MELVILLE, N.Y., June 17, 2025 /PRNewswire/ -- Nikon Instruments Inc. (Nikon), a wholly owned subsidiary of Nikon Corporation, and Astellas Innovation Management LLC ("Astellas"), a wholly owned subsidiary of Astellas Pharma Inc., have entered a strategic collaboration to support......
16.06.25 - 13:24
MRI and Astellas to support Japanese drug-discovery startups (PBR)
 
This collaboration is expected to strengthen the country's role as an international hub for drug discovery. This new support is part of several programmes under the Medical Innovation The post MRI and Astellas to support Japanese drug-discovery startups appeared first on Pharmaceutical Business review....
13.06.25 - 07:54
Astellas And MRI Partner To Support Pharma Startups In Japan (AFX)
 
TOKYO (dpa-AFX) - Astellas Pharma and Mitsubishi Research Institute or MRI have agreed to work together to help drug-discovery startups in Japan expand globally. Their goal is to make Japan a stro......
13.06.25 - 07:12
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan (PR Newswire)
 
Accelerating the Growth of Globally Active Drug-Discovery Startups from Japan TOKYO, June 13, 2025 /PRNewswire/ -- Mitsubishi Research Institute, Inc. ("MRI") and Astellas Pharma Inc. ("Astellas") today announced that they have agreed on a memorandum of understanding to provide......
04.06.25 - 13:09
Astellas Chooses Veeva Vault CRM as Global Standard (PR Newswire)
 
Vault CRM will support Astellas' commercial agility and execution PLEASANTON, Calif., June 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Astellas has chosen Veeva Vault CRM globally and Veeva China CRM for China. "At Astellas, we discover and deliver transformative......
30.05.25 - 02:18
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 (PR Newswire)
 
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 - - XNW27011 has demonstrated encouraging monotherapy efficacy in an ongoing Phase 1/2 study of patients with solid tumors,......
28.05.25 - 16:01
Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers (PR Newswire)
 
Building on a successful inaugural year, the initiative sponsored by Astellas' Patient Centricity team continues to connect individuals with vital resources and support from patient advocacy organizations NORTHBROOK, Ill., May 28, 2025 /PRNewswire/ -- Astellas Patient Centricity is......
27.05.25 - 17:30
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? (Zacks)
 
Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year....
23.05.25 - 05:54
Astellas And Pfizer′s XTANDI Shows Long-Term Survival Benefits In Metastatic Prostate Cancer (AFX)
 
NEW YORK CITY (dpa-AFX) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES study, reporting a five-year......
22.05.25 - 23:03
Astellas and Pfizer′s XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer (PR Newswire)
 
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Am Anfang war die Kraft. - Paula Modersohn-Becker
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!